tetano
Editor, Senior Moderator
Vaccine
. 2020 Nov 17;38(49):7697-7701.
doi: 10.1016/j.vaccine.2020.10.039. Epub 2020 Oct 19.
Identification of a dominant CD8 [SUP]+[/SUP] CTL epitope in the SARS-associated coronavirus 2 spike protein
Daisuke Muraoka[SUP] 1 [/SUP], Deng Situo[SUP] 2 [/SUP], Shin-Ichi Sawada[SUP] 3 [/SUP], Kazunari Akiyoshi[SUP] 3 [/SUP], Naozumi Harada[SUP] 4 [/SUP], Hiroaki Ikeda[SUP] 2 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2, has been spreading throughout the world. To date, there are still no approved human vaccines for this disease. To develop an effective vaccine, the establishment of animal models for evaluating post-vaccination immune responses is necessary. In this study, we have identified a CTL epitope in the SARS-CoV-2 spike (S) protein that could be used to measure the cellular immune response against this protein. Potential predicted CTL epitopes of the SARS-CoV-2 S protein were investigated by immunizing BALB/c mice with a recombinant of the receptor-binding domain (RBD) of the S protein. Then, CD8[SUP]+[/SUP] T cells specific for S-RBD were detected by stimulating with potential epitope peptides and then measuring the interferon-gamma production. Truncation of this peptide revealed that S-RBD-specific CD8[SUP]+[/SUP] T cells recognized a H2-D[SUP]d[/SUP]-restricted S[SUB]526-533[/SUB] peptide. In conclusion, this animal model is suitable for evaluating the immunogenicity of SARS-CoV-2 vaccines.
Keywords: COVID-19; CTL epitope; SARS-CoV-2; Spike protein.
. 2020 Nov 17;38(49):7697-7701.
doi: 10.1016/j.vaccine.2020.10.039. Epub 2020 Oct 19.
Identification of a dominant CD8 [SUP]+[/SUP] CTL epitope in the SARS-associated coronavirus 2 spike protein
Daisuke Muraoka[SUP] 1 [/SUP], Deng Situo[SUP] 2 [/SUP], Shin-Ichi Sawada[SUP] 3 [/SUP], Kazunari Akiyoshi[SUP] 3 [/SUP], Naozumi Harada[SUP] 4 [/SUP], Hiroaki Ikeda[SUP] 2 [/SUP]
Affiliations
- PMID: 33164796
- DOI: 10.1016/j.vaccine.2020.10.039
Abstract
Coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2, has been spreading throughout the world. To date, there are still no approved human vaccines for this disease. To develop an effective vaccine, the establishment of animal models for evaluating post-vaccination immune responses is necessary. In this study, we have identified a CTL epitope in the SARS-CoV-2 spike (S) protein that could be used to measure the cellular immune response against this protein. Potential predicted CTL epitopes of the SARS-CoV-2 S protein were investigated by immunizing BALB/c mice with a recombinant of the receptor-binding domain (RBD) of the S protein. Then, CD8[SUP]+[/SUP] T cells specific for S-RBD were detected by stimulating with potential epitope peptides and then measuring the interferon-gamma production. Truncation of this peptide revealed that S-RBD-specific CD8[SUP]+[/SUP] T cells recognized a H2-D[SUP]d[/SUP]-restricted S[SUB]526-533[/SUB] peptide. In conclusion, this animal model is suitable for evaluating the immunogenicity of SARS-CoV-2 vaccines.
Keywords: COVID-19; CTL epitope; SARS-CoV-2; Spike protein.